These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15186726)

  • 1. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma.
    Brand JM; Meller B; Von Hof K; Luhm J; Bähre M; Kirchner H; Frohn C
    Stem Cells Dev; 2004 Jun; 13(3):307-14. PubMed ID: 15186726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma.
    Meller B; Frohn C; Brand JM; Lauer I; Schelper LF; von Hof K; Kirchner H; Richter E; Baehre M
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):403-7. PubMed ID: 14685783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells in the treatment of high-risk acute leukaemia.
    Locatelli F; Moretta F; Brescia L; Merli P
    Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation.
    Pascal V; Brunet C; Pradel V; Thirion X; Andre P; Faucher C; Sampol J; Dignat-George F; Blaise D; Vivier E; Chabannon C
    Leukemia; 2002 Nov; 16(11):2259-66. PubMed ID: 12399971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
    Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
    Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
    Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
    Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of activated donor-type NK cells on allogeneic bone marrow transplantation in mice].
    Sun K; Zhang M; Tian Z
    Zhonghua Xue Ye Xue Za Zhi; 1999 Sep; 20(9):477-9. PubMed ID: 11721413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products.
    Skeate R; Singh C; Cooley S; Geller M; Northouse J; Welbig J; Slungaard A; Miller J; McKenna D
    Transfusion; 2013 Feb; 53(2):419-23. PubMed ID: 23113867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered donor and recipient Ly49+ NK cell subsets in allogeneic H-2d --> H-2b and H-2b --> H-2d bone marrow chimeras.
    Korten S; Wilk E; Gessner JE; Meyer D; Schmidt RE
    J Immunol; 1999 Dec; 163(11):5896-905. PubMed ID: 10570275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch.
    Vampa ML; Norman PJ; Burnapp L; Vaughan RW; Sacks SH; Wong W
    Transplantation; 2003 Oct; 76(8):1220-8. PubMed ID: 14578757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study.
    Yoon SR; Lee YS; Yang SH; Ahn KH; Lee JH; Lee JH; Kim DY; Kang YA; Jeon M; Seol M; Ryu SG; Chung JW; Choi I; Lee KH
    Bone Marrow Transplant; 2010 Jun; 45(6):1038-46. PubMed ID: 19881555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
    Gärtner F; Hieke S; Finke J; Bertz H
    Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation.
    Hu B; Bao G; Zhang Y; Lin D; Wu Y; Wu D; Liu H
    J Immunol; 2012 Aug; 189(4):1661-70. PubMed ID: 22798668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
    J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
    Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
    Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contact-dependent endothelial class II HLA gene activation induced by NK cells is mediated by IFN-gamma-dependent and -independent mechanisms.
    Watson CA; Petzelbauer P; Zhou J; Pardi R; Bender JR
    J Immunol; 1995 Apr; 154(7):3222-33. PubMed ID: 7897208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.